Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic responseAmir Fathi, Yi‐Bin Chen, Cedric T. Hill et al.|Blood|2012Cited by 123
Isocitrate Dehydrogenase 1 (<i>IDH1</i>) Mutation in Breast Adenocarcinoma Is Associated With Elevated Levels of Serum and Urine 2-HydroxyglutarateAmir T. Fathi, Darrell R. Borger, Hossein Sadrzadeh et al.|The Oncologist|2014Cited by 74
Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemiaAmir T. Fathi, Yi‐Bin Chen, Seth A. Wander et al.|Haematologica|2016Cited by 43
Isocitrate dehydrogenase 1 and 2 mutations, 2‐hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemiaAndrew M. Brunner, Amir Fathi, Donna Neuberg et al.|Cancer|2018Cited by 33
Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance‐conferring FLT3/tyrosine kinase domain/F691 mutationAmir T. Fathi, Mark J. Levis, Traci M. Blonquist et al.|Cancer|2017Cited by 31